IONIS-AGT-LRx (80 mg weekly via subcutaneous injection) has been evaluated in 2 double-blind, placebo-controlled trials in subjects with hypertension, either as monotherapy (25 patients) or as an add-on on top of ACE inhibitors/ARBs (26 patients) versus placebo for up to 2 months. The gene discussed is ACE; the disease is hypertensive disorder.